SEQUENT SCIENTIFIC
|
SEQUENT SCIENTIFIC Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -4.86 | 1.65 | 3.84 | 2.81 | 1.97 |
| CEPS(Rs) | -2.66 | 3.88 | 6.24 | 5.34 | 4.00 |
| DPS(Rs) | - | - | 0.50 | - | 0.20 |
| Book NAV/Share(Rs) | 25.76 | 25.97 | 28.98 | 27.10 | 27.86 |
| Tax Rate(%) | 11.39 | 15.43 | 23.55 | 12.79 | 3.41 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 0.82 | 7.59 | 15.42 | 14.14 | 11.80 |
| EBIT Margin(%) | -7.02 | 4.76 | 11.83 | 10.77 | 8.66 |
| Pre Tax Margin(%) | -9.47 | 3.67 | 10.03 | 7.81 | 5.56 |
| PAT Margin (%) | -8.39 | 3.10 | 7.67 | 6.81 | 5.37 |
| Cash Profit Margin (%) | -4.56 | 6.68 | 11.39 | 11.01 | 9.33 |
| Performance Ratios | |||||
| ROA(%) | -7.99 | 3.06 | 7.19 | 5.73 | 4.14 |
| ROE(%) | -18.95 | 6.56 | 15.00 | 12.06 | 8.63 |
| ROCE(%) | -9.71 | 7.01 | 16.24 | 12.59 | 9.24 |
| Asset Turnover(x) | 0.95 | 0.98 | 0.94 | 0.84 | 0.77 |
| Sales/Fixed Asset(x) | 1.65 | 1.83 | 1.80 | 1.72 | 1.74 |
| Working Capital/Sales(x) | 5.73 | 5.32 | 5.37 | 5.75 | 6.39 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.61 | 0.55 | 0.56 | 0.58 | 0.58 |
| Receivable days | 84.11 | 85.48 | 89.12 | 90.45 | 92.53 |
| Inventory Days | 87.10 | 77.50 | 64.84 | 63.56 | 61.85 |
| Payable days | 109.97 | 111.61 | 117.51 | 129.62 | 124.30 |
| Valuation Parameters | |||||
| PER(x) | - | 81.14 | 62.69 | 27.61 | 36.45 |
| PCE(x) | -27.32 | 34.51 | 38.59 | 14.55 | 17.95 |
| Price/Book(x) | 2.82 | 5.15 | 8.31 | 2.87 | 2.58 |
| Yield(%) | - | - | 0.21 | - | 0.28 |
| EV/Net Sales(x) | 1.52 | 2.53 | 4.52 | 1.86 | 1.95 |
| EV/Core EBITDA(x) | 118.11 | 29.76 | 27.91 | 12.18 | 15.17 |
| EV/EBIT(x) | -21.21 | 52.09 | 38.21 | 16.93 | 22.11 |
| EV/CE(x) | 1.38 | 2.41 | 4.26 | 1.50 | 1.45 |
| M Cap / Sales | 1.27 | 2.35 | 4.39 | 1.64 | 1.71 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 0.57 | 3.76 | 15.47 | 13.46 | 22.58 |
| Core EBITDA Growth(%) | -84.74 | -45.45 | 22.18 | 35.03 | 34.20 |
| EBIT Growth(%) | -248.67 | -57.33 | 24.06 | 41.56 | 61.66 |
| PAT Growth(%) | -372.49 | -57.14 | 27.31 | 44.25 | 458.27 |
| EPS Growth(%) | -394.58 | -57.09 | 36.53 | 42.79 | -88.60 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.62 | 0.49 | 0.31 | 0.51 | 0.47 |
| Current Ratio(x) | 1.45 | 1.50 | 1.49 | 1.41 | 1.38 |
| Quick Ratio(x) | 0.83 | 0.86 | 0.98 | 0.98 | 0.92 |
| Interest Cover(x) | -2.88 | 4.36 | 6.60 | 3.63 | 2.80 |
| Total Debt/Mcap(x) | 0.22 | 0.09 | 0.04 | 0.18 | 0.18 |
Compare Financial Ratios of peers of SEQUENT SCIENTIFIC
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SEQUENT SCIENTIFIC | ₹3,053.9 Cr | -0.9% | -21.7% | 48.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹356,001.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,813.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹100,075.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,325.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,553.2 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
SEQUENT SCIENTIFIC Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SEQUENT SCIENTIFIC | -0.9% |
-21.7% |
48.1% |
| SENSEX | 0.5% |
1.4% |
23.5% |
You may also like the below Video Courses
